![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Genentech and JHL Biotech Settle Trade Secret Suit
Genentech and JHL Biotech Settle Trade Secret Suit
September 17, 2019
JHL Biotech has conceded to Genentech in a lawsuit over JHL’s development of biosimilars, to settle claims that it used stolen trade secrets to develop copycat drugs.
The settlement will see JHL end development and clinical trials of biosimilar versions of four leading Genentech products: Rituxan (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab) and Pulmozyme (dornase alfa).
Under the settlement agreement, JHL is also required to destroy all cell lines and cell banks associated with the medicines.
Upcoming Events
-
21Oct